Biomaterials for vaccine-based cancer immunotherapy

Zhang, Rui; Billingsley, Margaret M.; Mitchell, Michael J.

doi:10.1016/j.jconrel.2018.10.008

Cited by 155 publications

(129 citation statements)

References 406 publications

(491 reference statements)

Supporting

Mentioning

120

Contrasting

Order By: Relevance

“…Consequently, ATP is released as a result of autophagy and high mobility group box 1 (HMGB1) is released as a result of late apoptosis. Accordingly, the chemoradiation therapy induces a considerable stress in tumor cells which may lead to intratumoral accumulation of dendritic cells, γδ T cells (producing IL17), and CD8 + T lymphocytes (producing IFN‐γ) . These are the possible reactions which may also contribute to the anticancer effects of ACA + RT treatment modality proposed and examined in this study.…”

Section: Discussionmentioning

confidence: 90%

Enhancement of chemoradiation by co‐incorporation of gold nanoparticles and cisplatin into alginate hydrogel

et al. 2019

View full text Add to dashboard Cite

Nonspecificity and high toxicity limit the treatment efficacy and safety of chemoradiation therapy. Effective tumor targeting of anticancer drugs and radiosensitizing agents is highly desirable to amplify the efficacy of this standard cancer therapy approach. To achieve this goal, we exploited the synergy of cisplatin and gold nanoparticles (AuNPs) co‐loaded into alginate hydrogel network, forming so‐called ACA nanocomplex, and X‐ray radiation. Cisplatin is a commonly used anticancer agent, and at the same time, along with AuNPs could function as radiosensitizers to enhance the radiation‐induced damages through various pathways. The ACA nanocomplex improved the therapeutic efficiency of standard chemotherapy and yielded 79% growth inhibition in CT26 colon adenocarcinoma tumor after 28 days, which was significantly higher than that of 9% for free cisplatin administration. Moreover, the combination of ACA nanocomplex with 6 MV X‐ray dramatically suppressed tumor growth up to 95%, showing 51% enhancement in antitumor activity compared to standard chemoradiation. The nanocomplex developed herein holds the promise to promote the efficiency of standard chemoradiation while maintaining the patient's safety through reducing the clinically administered doses of anticancer drug and X‐ray. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B:2658–2663, 2019.

show abstract

Section: Discussionmentioning

confidence: 90%

Enhancement of chemoradiation by co‐incorporation of gold nanoparticles and cisplatin into alginate hydrogel

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The combination of nucleic acid priming protein-enhanced immunoassay has made progress in the study of vaccines such as schistosomiasis, Japanese encephalitis, brucellosis, AIDS, tuberculosis 1-3 , malaria, etc., and its immune response is superior to a single nucleic acid vaccine or Protein vaccine [16 19]. Whether the N. meningitidis NMB0315 vaccine adopts the nucleic acid priming protein-enhanced combination immunization method is superior to the protein vaccine or nucleic acid vaccine alone [4][5][6][7][8][9][10][11][12] , has not been reported yet, and deserves further research and exploration.…”

Section: Figure 4 Antibody Titer Analysismentioning

confidence: 99%

Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect

Smith

2019

Preprint

View full text Add to dashboard Cite

This report demonstrates a novel method to explore and evaluate the specific humoral/cellular immune response levels and immunoprotective effects of NMB0315 nucleic acid vaccine, recombinant protein vaccine and nucleic acid vaccine + recombinant protein vaccine in combination with mice, and to further explore the effective immunization method for NMB0315 vaccine. This route provides experimental basis. Nucleic acid vaccines [pcDNA3 1(+) / NMB0315] and recombinant protein vaccines (pET 30a / NMB0315) were prepared in large quantities, and immunologically or separately immunized female BALB/c mice were determined by nucleic acid priming protein boosting method. The specific humoral/cell immune response level, the in vitro bactericidal titer of immune serum, and the immunoprotective effect of the vaccine on mice infected with group B meningococcus were observed. Serum-specific IgG, IgG1, IgG2a and genital lavage fluids induced by NMB0315 nucleic acid vaccine group (pNMB0315 CpG), protein vaccine group (rNMB0315 FA) and combined immunization group (pNMB0315 CpG+rNMB0315 FA). The specific sIgA level reached the peak in the eighth week, and the A450 values were in vitro, and the in vitro bactericidal antibody titers of the nucleic acid vaccine group, the protein vaccine group and the combined immunization group were 1, 64, 1128, respectively. The immune protection rate of experimental mice were 70%, 95% and 80%, respectively. At 2, 4, 6, and 8 weeks, the ratio of IgG2a / IgG1 in the nucleic acid vaccine group, the recombinant protein vaccine group, and the combined immunization vaccine group was less than 1.

show abstract

“…7, when immunized with the same dose of DNA, the neutralizing antibody of PLGA/CTAB-DNA microparticle immunization group was higher than that of naked DNA vaccine immunization group 8 weeks after the first dose (P<0. 05), and at low dose [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] .…”

Section: Figure 3 In Vitro Luciferase Expressionmentioning

confidence: 99%

“…The idea [3]. Polylactic acid-glycolic acid (PLGA) is a biodegradable polymer with good biocompatibility and is widely used in pharmaceuticals, especially as a macromolecular drug delivery carrier [4][5]. The positively charged PLGA/CTAB microparticles prepared by PLGA can effectively adsorb and protect DNA, and the slow release can improve the half-life and immune effect of the adsorbed DNA vaccine in vivo [6].…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity assessment of PRRS polylactic acid glycolic acid DNA vaccine

Smith

Kowalski

2019

Preprint

View full text Add to dashboard Cite

In order to enhance the immune effect of DNA vaccine, poly(lactide-co-glycolide (PLGA)] microparticles were prepared by solvent evaporation method, and the porcine reproductive and respiratory syndrome (PRRS) DNA vaccine pCI-ORF5 was adsorbed to the porcine reproductive and respiratory syndrome (PRRS) DNA vaccine. The surface of the microparticles was used to detect the amount of DNA adsorbed by PLGA microparticles, in vitro release, and immunogenicity in mice. The results showed that the DNA adsorption capacity of PLGA particles could reach 0.9% within 6h, and the release in vitro was affected by many factors such as CTAB content, PLGA molecular weight, PLGA concentration and internal water phase volume. After immunizing mice with the naked DNA vaccine, PLGA microparticles were found to significantly enhance the humoral and cellular immunity induced by the adsorbed DNA vaccine, indicating that it has a good application prospect as a vector for delivering DNA vaccines.

show abstract

Biomaterials for vaccine-based cancer immunotherapy

Cited by 155 publications

References 406 publications

Enhancement of chemoradiation by co‐incorporation of gold nanoparticles and cisplatin into alginate hydrogel

Enhancement of chemoradiation by co‐incorporation of gold nanoparticles and cisplatin into alginate hydrogel

Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect

Immunogenicity assessment of PRRS polylactic acid glycolic acid DNA vaccine

Contact Info

Product

Resources

About